Press Releases July 30, 2026 05:00 PM

FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026

FocalTherics schedules Q2 2026 financial results announcement and webcast for August 13, 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
FOCL

FocalTherics, a global leader in robotic focal therapy and minimally invasive medical devices, will release its second quarter 2026 financial results after market close on August 13, 2026. The company will host a conference call and webcast featuring senior management to discuss the results.

FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026
FOCL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • FocalTherics is releasing Q2 2026 financial results on August 13, 2026.
  • The company specializes in robotic focal therapy using focused ultrasound technology.
  • A conference call and webcast will allow investors and analysts to engage with management about the quarterly performance.

FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026

Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT

AUSTIN, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- FocalTherics (Nasdaq: FOCL) (the “Company”), the global leader in robotic focal therapy, today announced that it will release its financial results for the second quarter ended June 30, 2026, after market close on Thursday, August 13, 2026. 

An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.

Call Details:

Date: Thursday, August 13, 2026, at 4:30 p.m. Eastern TimeDomestic: 1-800-245-3047International: 1-203-518-9765Passcode: FOCAL Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1767672&tp_key=2d69d92ca7

About FocalTherics
A recognized global leader in Robotic Focal Therapy, FocalTherics develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology. The Company’s flagship platform, Focal One Robotic HIFU, combines advanced imaging, real-time treatment planning, robotic precision, and HIFU technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving quality of life. FocalTherics is committed to expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and global market development initiatives. For more information about FocalTherics, visit FocalTherics.com.

Investor Contacts
Louisa Smith
Gilmartin Group
[email protected]


Risks

  • Financial results may reflect uncertainties or challenges not detailed in the release, impacting stock performance.
  • The adoption and market expansion of novel robotic focal therapy technology may face competitive or regulatory risks.
  • Clinical outcomes and physician adoption rates could affect revenue growth and market position.

More from Press Releases

U.S. Air Force and Northrop Grumman Assemble Inert Missile, Progress Toward Sentinel Flight Testing Sep 14, 2026 Toll Brothers Announces New Luxury Community Opening in Redondo Beach, California Sep 14, 2026 CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition Sep 14, 2026 Video Opportunity: ‘Better Together Days’ volunteer blitz Sep 14, 2026 SEALSQ’s CEO, Carlos Moreira Joins the Board of Trustees of the World Law Foundation and Proposes Creation of a Global AI Chapter Sep 14, 2026